medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2009, Number 5

<< Back Next >>

Rev Invest Clin 2009; 61 (5)

Copper sulfate prevents tyrosine hydroxylase reduced activity and motor deficits in a Parkinson’s disease model in mice

Alcaraz-Zubeldia M, Boll-Woehrlen MC, Montes-López S, Pérez-Severiano F, Martínez-Lazcano JC, Díaz-Ruiz A, Ríos C

Language: English
References: 37
Page: 405-411
PDF size: 84.90 Kb.


ABSTRACT

Introduction. Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the presence of motor disturbances, derived from the striatal dopamine depletion. Previously, we reported that CuSO4 pretreatment blocked an oxidative stress marker (lipid peroxidation) and prevented the striatal dopamine depletion induced by the administration of the 1-methyl-4-phenylpiridinium (MPP+), the toxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a model of PD. Objective. To determine if tyrosine hydroxylase (TH), the rate-limiting synthetic enzyme of dopamine, is implicated in the neuroprotective effect of CuSO4 pretreatment, and if this neuroprotective effect is able to prevent the hypokinetic state (measured as spontaneous locomotor activity, SLA) induced by the experimental model of PD. Material and methods. C57 Black/6J mice received a single dose of CuSO4 (2.5 mg/kg, i.p.) either 16 or 24 h before the administration of MPP+ (18 µg/3 µl, i.c.v.). Twenty four hours later, mice SLA was registered and animals sacrificed. Striatal L-DOPA accumulation derived from the administration of a central dopamine descarboxilase inhibitor was evaluated, a strategy considered as a reliable indirect analysis of tyrosine hydroxylase activity (THA). Results. Administration of MPP+ decreased SLA (-52%; p = 0.003) as compared to control group values, whereas those mice pretreated with CuSO4 16 h before MPP+, increased SLA by 47% as compared with control group (p = 0.015). Mice pretreated with CuSO4 24 h before MPP+, also showed a statistically significant increase in SLA (71%; p = 0.02), when compared with control group. As a consequence of MPP+ administration, THA was also reduced as compared to control group values (32%; p ‹ 0.05). Reduction of THA was blocked when mice were pretreated with CuSO4 16 h before MPP+. Moreover, mice receiving the CuSO4 24 h before MPP+ showed a significant increase (38%; p ‹ 0.05) in THA when compared with control group. Conclusion. Results suggest that preservation of THA participates in the neuroprotective effects derived from the copper supplementation, a phenomenon that avoid the hypokinetic state induced by the MPP+ experimental model of PD.


REFERENCES

  1. Ebadi M, Srinivasan SK, Baxi MD. Oxidative stress and antioxidant therapy in Parkinson’s disease. Prog Neurobiol 1996; 48: 1-19.

  2. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford: Lavendon Press; 1985, p. 374.

  3. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993; 90: 7915-22.

  4. Sorenson JRJ. Copper complexes: A physiologic approach to treatment of chronic diseases. Compr Ther 1985; 11(4): 49-57.

  5. Miyajima H, Takahashi Y, Kono S. Aceruloplasminemia, an inherited disorder of iron metabolism. Biometals 2003; 16(1): 205-13.

  6. Alcaraz-Zubeldia M, Rojas P, Boll C, Rios C. Neuroprotective effect of acute and chronic administration of copper (II) sulfate against MPP+ neurotoxicity in mice. Neurochem Res 2001; 26(1): 59-64.

  7. Pzerdborski S, Kostic V, Jackson-Lewis V, Naini AB, Simonetti S, Cadet JL. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-Methyl-4-phenyl-1,2,3,6- Tetrahydropyridine-induced neurotoxicity. J Neurosci 1992; 12: 1658-67.

  8. Haas RH, Nasirian F, Nakano K, Ward D, Hill R, Shults CW. Low platelet mitochondrial Complex I and Complex II/III activity in early untreated Parkinson’s Disease. Ann Neurol 1995; 37: 714-22.

  9. Alcaraz-Zubeldia M, Montes S, Ríos C. Participation of manganese- superoxide dismutase in the neuroprotection exerted by copper sulfate against 1-methyl 4-phenylpyridinium neurotoxicity, Brain Res Bull 2001; 55(1): 277-9.

  10. Jackson-Lewis V, Smeyne RJ. MPTP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Minireview. Neurotox Res 2005; 7(3): 193-202.

  11. Kappock TJ, Caradona JP. Pterin-dependent amino acid hydroxylases.Chem Rev 1996; 96: 2659-756.

  12. Haavic J, Toska K. Tyrosine hydroxylase and Parkinson’s disease. Mol Neurobiol 1998; 16(3): 285-309.

  13. Ara J, Przedborski S, Naini AB, Jackson-Lewis V, Trifiletti RR, Horwitz J, Ischiropoulos H. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), Proc Natl Acad Sci USA 1998; 95(13): 7659-63.

  14. Cooper JR, Bloom FE, Roth RH. Dopamine. In: The biochemical basis of Neuropharmacology. 6th Ed. USA: Oxford Univ. Press; 1991, p. 285-337.

  15. Kobayashi K, Sano H. Dopamine deficiency in mice. Brain Dev 2000; 22: S54-S60.

  16. Fredriksson A, Archer T. MPTP-induced behavioral and biochemical deficits a parametric analysis. J Neural Transm 1995; 7: 123-32.

  17. Gutiérrez-Reyes EY, Albores A, Ríos C. Increase of striatal dopamine release by cadmium in nursing rats and its prevention by dexamethasone-induced metallothionein. Toxicology 1998; 131: 145-54.

  18. Glowinski J, Iversen LL. Regional studies of catecholamines in the rat brain. Disposition of +3H-Norepinephrine, +3H-Dopamine and +3H-DOPA in various regions of the brain. J Neurochem 1966; 13: 655-69.

  19. González M, Reyes-Jara A, Suazo M, Jo WJ, Vulpe C. Expression of copper-related genes in response to copper load. Am J Clin Nutr 2008; 88(3): 830-4.

  20. Pérez-Severiano F, Bermúdez-Ocaña DY, López-Sánchez P, Ríos C, Granados-Soto V. Spinal nerve ligation reduces nitric oxide synthase activity and expression: effect of resveratrol. Pharmacol Biochem Behav 2008; 90(4): 742-7.

  21. Langston JW, Ballard PA, Tetrud JW. Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science 1983; 219: 979-80.

  22. Przedborski S, Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov Des 1998; 13(1): 35-8.

  23. Maruyama W, Naoi M. Inhibition of tyrosine hydroxylase by a dopamine neurotoxin, 1-methyl-4-phenylpyridinium ion: depletion of allostery to the biopterin cofactor. Life Sci 1994; 55(3): 207-12.

  24. Kuhn DM, Arthur RE Jr, Thomas DM, Elferink LA. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson’s Disease. J Neurochem 1999; 73(3): 1309-17.

  25. Torreilles F, Salman’Tabcheh S, Guérin M-C, Torreilles J. Neurodegenerative disorders: the role of peroxynitrite. Brain Res Rev 1999; 30:153-63.

  26. Rubio-Osornio M, Montes S, Pérez-Severiano F, Aguilera P, Floriano-Sánchez E, Monroy-Noyola A, et al. Copper reduces striatal protein nitration and tyrosine hydroxylase inactivation induced by MPP+ in rats. Neurochem Int 2009; 54: 447-51.

  27. Sitasawad S, Deshpande M, Katdare M, Tirth S, Parab P. Beneficial effect of supplementation with copper sulfate on STZdiabetic mice (IDDM). Diab Res Clin Pract 2001; 52: 77-84.

  28. Simonian, NA, Coyle, JT. Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 1996; 36: 83-106.

  29. Klivenyi P, Andreassen OA, Ferrante RJ, Lancelot E, Reif D, Beal MF. Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity. Neuroreport 2000; 11(6): 1265-8.

  30. Colasanti M, Perschini T, Venturini G, Polticelli F, Musci G. Modulation of the nitric oxide pathway by copper in glial cells. Biochem Biophys Res Commun 2000; 275: 776-82.

  31. Perry JM, Zhao Y, Marletta MA. Cu+2 and Zn+2 inhibit nitricoxide synthase through an interaction with the reductase domain. J Biol Chem 2000; 275(19): 14070-6.

  32. Shiva S, Wang X, Ringwood LA, Xu X, Yuditskaya S, Annavajjhala V, et al. Ceruloplasmin is a NO oxidase and nitrite synthase that determines endocrine NO homeostasis. Nat Chem Biol 2006; 2(9): 486-93.

  33. Murthy RC, Lal S, Saxena DK, Shukla GS, Ali MM, Chandra SV. Effect of manganese and copper interaction on behaviour and biogenic amines in rats fed a 10% casein diet. Chem Biol Interact 1981; 37 (3): 299-308.

  34. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson disease. J Neurosci 2001; 21 (10): RC143.

  35. El Yacoubi M, Ledent C, Menard JF, Parmentier M, Costentin J, Vaugeois JM. The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors. Br J Pharmacol 2000; 129: 1465-73.

  36. Marangos PJ, Patel J, Martino AM, Dilli M, Boulenger JP. Differential binding properties of adenosine receptor agonists and antagonists in brain. J Neurochem 1983; 41(2): 367-74.

  37. Pong K, Doctrow SR, Baudry M. Prevention of 1-methyl-4- phenylpyridinium- and 6-hydroxydopamine-induced nitration of tyrosine hydroxylase and neurotoxicity by EUK-134, a superoxide dismutase and catalase mimetic in cultured dopaminergic neurons. Brain Res 2000; 881(2): 182-9.




2020     |     www.medigraphic.com